Reblozyl (luspatercept-aamt) / BMS, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 2 Diseases   40 Trials   40 Trials   1659 News 


«12345678910111213...1718»
  • ||||||||||  Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
    Targeting Dyserythropoiesis in Clinical Practice (Auditorium; Virtual) -  Apr 25, 2023 - Abstract #MDS2023MDS_123;    
    Luspatercept, effective in lower-risk MDS with SF3B1 mutations, on the other hand, seem to act through making later stages if erythropoiesis more effective...More than 30% of MDS patients receive either EPO or azacytidine as first-line intervention, while other therapeutic options excluding stem cell transplantation are given to less than 3% of cases. Time-dependent multivariable analysis show that transfusion dependency at 8 months confers a stronger prognostic value both for lower and higher-risk MDS than RBCT status at diagnosis and hence could be used as a clinically useful contribution to patient information and clinical decision-making.
  • ||||||||||  sabatolimab (MBG453) / Novartis, Reblozyl (luspatercept-aamt) / BMS, Merck (MSD), magrolimab (GS-4721) / Ono Pharma, Gilead
    Antibody-Based Therapy of MDS (Auditorium; Virtual) -  Apr 25, 2023 - Abstract #MDS2023MDS_122;    
    Magrolimab is an anti-CD47 antibody which is currently in late stage development in MDS; it has been combined with azacitidine based on preclinical data suggesting synergistic activity and is currently being studied in the phase III ENHANCE study comparing azacitidine to azacitidine+magrolimab...Sabatolimab is an anti-TIM-3 antibody currently being studied in MDS in the phase III STIMULUS trial, comparing azacitidine+placebo to azacitidine+sabatolimab...Luspatercept is a fusion protein which incorporates the Fc portion of the IgG heavy chain, fused to a modified extracellular domain of the activin receptor type IIB (ActRIIB)...Together, antibody-based therapies represent a promising new therapeutic area in MDS. This abstract will review the current landscape of antibody-based therapeutics in MDS, including data for their use to target immune checkpoints, cancer-specific ligands, and also as part of ligand traps for relevant signaling pathways that are overactive in MDS.
  • ||||||||||  imetelstat (GRN163L) / Geron, Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen, Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
    Therapies of Anemia (Excluding MDS-RS Treatment) (Auditorium; Virtual) -  Apr 25, 2023 - Abstract #MDS2023MDS_81;    
    Luspatercept, a TGFbeta family ligand-trap induces nearly 50% of RBC transfusion independence in MDS with ring sideroblasts ( RS), but it has been shown to be active also in transfusion dependent non-RS LR MDS both in first line and after failure of ESA treatment. The telomerase inhibitor imetelstat has shown efficacy and disease modifying activity in LR MDS ESA refractory or relapsed, who did not receive lenalidomide or hypomethylating agents...Another approach has been represented by the oral hypoxia
  • ||||||||||  Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
    Review, Journal:  Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes. (Pubmed Central) -  Apr 25, 2023   
    Allogeneic hematopoietic stem cell transplant is the only potentially curative option and is usually reserved for medically fit patients with severe symptomatic cytopenias who failed all standard options and/or the disease is progressing toward higher risk categories. Fortunately, novel investigational therapies are rapidly emerging by targeting different biological processes contributing to MDS pathogenesis, and eligible patients should be managed in clinical trials if available.
  • ||||||||||  lenalidomide / Generic mfg., Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
    Review, Journal:  State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes. (Pubmed Central) -  Mar 2, 2023   
    Hypomethylating agents can be option for patients with higher risk features or thrombocytopenia/neutropenia. Refractory cytopenias still poses frustration as options are limited and there is need to add more treatments to our armamentarium.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
    Try Luspatercept before Venetoclax (Twitter) -  Feb 19, 2023   
  • ||||||||||  Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
    Journal:  Role of Luspatercept in the Management of Lower-Risk Myelodysplastic Syndromes. (Pubmed Central) -  Feb 7, 2023   
    The most common adverse events (AEs), including fatigue, asthenia, dizziness, and diarrhea, were more frequent during the first 4 treatment cycles and subsequently declined. This review provides a comprehensive overview of luspatercept treatment administration, including the mechanism of action, efficacy and safety data, management of dosing, and AEs associated with luspatercept treatment of patients with LR-MDS.
  • ||||||||||  Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
    Journal:  Myelodysplastic Syndromes: New Methods of Diagnosis, Prognostication, and Treatment. (Pubmed Central) -  Feb 1, 2023   
    Trial completion date: Feb 2028 --> Sep 2027 Once a precise diagnosis has been established, new prognostic instruments such as the IPSS-M enable risk-adapted treatment based on the biological aspects of the patient's disease as well as his or her age and comorbidities.
  • ||||||||||  Review, Journal:  Rise of the planet of rare anemias: An update on emerging treatment strategies. (Pubmed Central) -  Jan 27, 2023   
    PNH treatment is moving from the intravenous anti-C5 eculizumab to its long-term analog ravulizumab, and to subcutaneous and oral proximal inhibitors (anti-C3 pegcetacoplan, factor D and factor B inhibitors danicopan and iptacopan)...Finally, the addition of eltrombopag significantly ameliorated AA outcomes, and data regarding the alternative agent romiplostim are emerging. The accelerated evolution of treatment strategies will need further effort to identify the best candidate for each treatment in the precision medicine era.
  • ||||||||||  Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
    Trial completion date, Trial primary completion date:  Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (?)-Thalassemia (clinicaltrials.gov) -  Jan 19, 2023   
    P2a,  N=54, Recruiting, 
    The accelerated evolution of treatment strategies will need further effort to identify the best candidate for each treatment in the precision medicine era. Trial completion date: Sep 2033 --> Nov 2026 | Trial primary completion date: Feb 2031 --> Jun 2026
  • ||||||||||  Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
    Luspatercept? 🤔 (Twitter) -  Jan 18, 2023   
  • ||||||||||  Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
    Luspatercept (Twitter) -  Jan 15, 2023